AR074055A1 - Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo - Google Patents
Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodoInfo
- Publication number
- AR074055A1 AR074055A1 ARP090104083A ARP090104083A AR074055A1 AR 074055 A1 AR074055 A1 AR 074055A1 AR P090104083 A ARP090104083 A AR P090104083A AR P090104083 A ARP090104083 A AR P090104083A AR 074055 A1 AR074055 A1 AR 074055A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- vector
- polynucleotide
- sequence
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica que comprende: a) un vector de expresion, donde el vector comprende uno o más polinucleotidos que codifican uno o más polipéptidos seleccionados entre el grupo compuesto por una AHSV VP, una variante o fragmento de la AHSV VP, y una mezcla de ellos; y b) un vehículo, diluyente o excipiente farmacéutica o veterinariamente aceptable. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, caracterizada porque el vector de expresion es un vector de expresion in vivo o in vitro. Reivindicacion 8: La composicion de acuerdo con la reivindicacion 1, caracterizada porque el vector se selecciona entre el grupo que comprende vCP2377 (SEQ ID Ns 17), vCP2383 (SEQ ID Ns 27), vCP2398 (SEQ ID Ns 41), y mezclas de ellos. Reivindicacion 9: La composicion de acuerdo con la reivindicacion 1, caracterizada porque el vehículo, diluyente o excipiente farmacéutica o veterinariamente aceptable es CARBOPOL. Reivindicacion 11: El vector de acuerdo con la reivindicacion 10, caracterizado porque el polinucleotido se selecciona entre el grupo que comprende a) un polinucleotido que codifica un polipéptido que tiene al menos 80% de identidad de secuencia con un polipéptido que tiene la secuencia que se establece en la SEQ ID Ns 1, 2, 20, 21, 30,31, 35, 36, 44, 45, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, o 63; b) un polinucleotido que tiene al menos 70% de identidad de secuencia con un polinucleotido que codifica un polipéptido que tiene la secuencia que se establece en la SEQ ID Ns 1, 2, 20, 21, 30, 31, 35, 36, 41, 45, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, o 63; y c) un polinucleotido que tiene al menos 70% de identidad con un polinucleotido que tiene la secuencia que se establece en la SEQ ID Ns 3, 4, 5, 6, 17, 18, 19, 22, 27, 28, 29, 32, 33, 34, 41, 42, 43, 48, o 50; donde el vector es un vector de expresion in vivo o en un vector de expresion in vitro. Reivindicacion 16: Una célula huésped transformada con el vector de acuerdo con la reivindicacion 10. Reivindicacion 20: Un polinucleotido aislado, caracterizado porque el nucleotido comprende: a) una secuencia de nucleotidos que tiene al menos 80% de identidad de secuencia con un polinucleotido que tiene la secuencia que se establece en la SEQ ID Ns 48 o 50; b) una secuencia de nucleotidos que codifica un polipéptido que tiene al menos 80% de identidad de secuencia con un polipéptido que tiene la secuencia que se establece en la SEQ ID Ns 49 o 51; o c) una secuencia de nucleotidos que tiene al menos 70% de identidad de secuencia con un polinucleotido que codifica un polipéptido que tiene la secuencia que se establece en la SEQ ID Ns 49 o 51.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10807508P | 2008-10-24 | 2008-10-24 | |
| US16351709P | 2009-03-26 | 2009-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074055A1 true AR074055A1 (es) | 2010-12-22 |
Family
ID=41818403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104083A AR074055A1 (es) | 2008-10-24 | 2009-10-23 | Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8168200B2 (es) |
| EP (1) | EP2358742B1 (es) |
| JP (1) | JP2012506699A (es) |
| KR (1) | KR101719005B1 (es) |
| CN (1) | CN102245627A (es) |
| AP (1) | AP3334A (es) |
| AR (1) | AR074055A1 (es) |
| AU (1) | AU2009308331C1 (es) |
| BR (2) | BRPI0920622B1 (es) |
| CA (1) | CA2741333C (es) |
| CL (1) | CL2011000922A1 (es) |
| EA (1) | EA024111B1 (es) |
| ES (1) | ES2681693T3 (es) |
| MX (1) | MX2011004219A (es) |
| NZ (2) | NZ598605A (es) |
| PL (1) | PL2358742T3 (es) |
| PT (1) | PT2358742T (es) |
| WO (1) | WO2010048394A2 (es) |
| ZA (1) | ZA201103031B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024111B1 (ru) * | 2008-10-24 | 2016-08-31 | Мериал Лимитед | Вакцина против вируса африканской чумы лошадей |
| MX360415B (es) | 2012-02-14 | 2018-10-31 | Merial Inc | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. |
| EP3149158B1 (en) * | 2014-11-04 | 2017-10-11 | Deltamune (PTY) Limited | Live attenuated african horsesickness virus |
| US10574993B2 (en) | 2015-05-29 | 2020-02-25 | Qualcomm Incorporated | Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design |
| WO2019179966A1 (en) * | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | Ehv insertion site ul43 |
| CN116041447A (zh) * | 2022-12-29 | 2023-05-02 | 北京亿森宝生物科技有限公司 | 一种检测非洲马瘟病毒的试剂盒及其应用 |
| CN116656731B (zh) * | 2023-05-25 | 2024-04-12 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法 |
| CN117737310A (zh) * | 2024-01-26 | 2024-03-22 | 中国农业科学院北京畜牧兽医研究所 | 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| ZA976424B (en) * | 1996-07-05 | 1999-01-22 | Agricultural Research Council | Nucleic acid sequences coding for african horsesickness virus outer capsid components |
| FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
| US7862821B2 (en) * | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| EA024111B1 (ru) * | 2008-10-24 | 2016-08-31 | Мериал Лимитед | Вакцина против вируса африканской чумы лошадей |
-
2009
- 2009-10-22 EA EA201100674A patent/EA024111B1/ru unknown
- 2009-10-22 CN CN2009801492091A patent/CN102245627A/zh active Pending
- 2009-10-22 ES ES09760655.2T patent/ES2681693T3/es active Active
- 2009-10-22 BR BRPI0920622-1A patent/BRPI0920622B1/pt active IP Right Grant
- 2009-10-22 AP AP2011005954A patent/AP3334A/xx active
- 2009-10-22 PL PL09760655T patent/PL2358742T3/pl unknown
- 2009-10-22 CA CA2741333A patent/CA2741333C/en active Active
- 2009-10-22 PT PT97606552T patent/PT2358742T/pt unknown
- 2009-10-22 NZ NZ598605A patent/NZ598605A/en unknown
- 2009-10-22 KR KR1020117011832A patent/KR101719005B1/ko active IP Right Grant
- 2009-10-22 BR BR122019001455-8A patent/BR122019001455B1/pt active IP Right Grant
- 2009-10-22 AU AU2009308331A patent/AU2009308331C1/en active Active
- 2009-10-22 WO PCT/US2009/061669 patent/WO2010048394A2/en active Application Filing
- 2009-10-22 NZ NZ592388A patent/NZ592388A/en unknown
- 2009-10-22 MX MX2011004219A patent/MX2011004219A/es active IP Right Grant
- 2009-10-22 US US12/604,048 patent/US8168200B2/en active Active
- 2009-10-22 JP JP2011533331A patent/JP2012506699A/ja active Pending
- 2009-10-22 EP EP09760655.2A patent/EP2358742B1/en active Active
- 2009-10-23 AR ARP090104083A patent/AR074055A1/es active IP Right Grant
-
2011
- 2011-04-21 CL CL2011000922A patent/CL2011000922A1/es unknown
- 2011-04-21 ZA ZA2011/03031A patent/ZA201103031B/en unknown
-
2012
- 2012-01-25 US US13/357,755 patent/US20120114691A1/en not_active Abandoned
-
2013
- 2013-10-22 US US14/060,023 patent/US20140120133A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074055A1 (es) | Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR065075A1 (es) | Vectores para la expresion multiple de genes | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| ES2454773T3 (es) | Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN | |
| AR083848A1 (es) | Polipeptidos con actividad de fosfolipasa c y polinucleotidos que los codifican | |
| AR067972A1 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer | |
| CO5700788A2 (es) | Composiciones y metodos para inmunoterapia especifica de wt1 | |
| ES2534752T3 (es) | Nuevo péptido antigénico contra el cáncer y utilización del mismo | |
| ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
| AR068428A1 (es) | Secuencias peptidicas y composiciones que las comprenden que proveen proteccion contra enfermedades transmitidas por artropodos | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| DK200601181A (da) | Fiskevaccine | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| PE20090683A1 (es) | Peptidos de senalizacion | |
| ES2676542T3 (es) | Composiciones de CDV recombinante y usos de las mismas | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| PE20180509A1 (es) | Composiciones y metodos para tratar la enfermedad celiaca | |
| JP2012506699A5 (es) | ||
| CL2021000549A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |